Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)
NCT03659435
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
58
Enrollment
OTHER
Sponsor class
Conditions
Bioequivalence
Interventions
DRUG:
RID-TDS 9.5 mg/24 h
DRUG:
Exelon® 9.5 mg/24 h
Sponsor
SocraTec R&D GmbH
Collaborators
[object Object]